| Friday, October 15, 2021 |
The BioNJ C Suite Summit will address “Transitioning to the ‘Next Normal’: Biopharma’s Role in Addressing the COVID-19 Crisis and What’s Next.” Partner Jacqueline R. Berman will be joined by Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research (CBER), Food & Drug Administration for "A Rapidly Evolving Regulatory Landscape – A Fireside Chat."
During the fireside chat, regulatory experts will share perspectives on emerging trends including the learnings from the “natural experiments” that took place during the pandemic, and what it means for the future of innovation and partnership between pharma and regulatory agencies with a special focus on pricing and policy reform.